Discussing the Debate: Leukocyte-Rich Platelet-Rich Plasma Versus Leukocyte-Poor Platelet-Rich Plasma

This editorial touches on the persistent debate related to platelet -rich plasma (PRP) therapy. It focuses on the different approaches involving leukocyte -rich and leukocyte -poor PRP formulations of the PRP. It looks into the reasons behind these approaches, their potential effects on clinical practice, i.e., pros and cons, and the evidence supporting each method within the field of regenerative medicine. Examining these different views highlights the complexity of PRP therapy. It's important to proceed carefully, relying on evidence to enhance patient outcomes. Understanding the ongoing debates can help healthcare professionals make informed decisions. We need to consider various factors before implementing PRP therapy, ensuring it's done responsibly.